Colorado cannabis market faces labeling and potency accuracy issues

Recent investigations and studies highlight significant compliance and accuracy issues within the Colorado cannabis market. A study conducted by researchers from the University of Colorado and MedPharm Holdings found that only 14.4% of recreational marijuana products met all six state-mandated labeling requirements. While most products included universal symbols and THC potency information, many lacked essential details such as expiration dates or ideal storage conditions. The study noted a major disparity between product types, with only 2.2% of flower products being fully compliant compared to 31% of concentrates.

Further concerns regarding product integrity were raised by Justin Singer, CEO of Ripple, who conducted independent testing on unmarked products from Denver-area dispensaries. The results indicated widespread issues, including THC potency inflation where labels claimed 34.2% more THC than actually present. Additionally, the testing revealed that several products failed to meet state safety standards due to the presence of yeast, mold, coliform, and pesticides.

Separately, in the context of federal rescheduling, Chief Administrative Law Judge Derek C. Julius ordered 294 corrections to the official transcript of an eleven-day hearing. These corrections addressed clerical errors and instances where the recorded testimony inadvertently contradicted the actual statements made by witnesses regarding cannabis shipments and legal compliance.